Significant potential of late- and mid-stage Novartis hematology portfolio to be s...
Novartis announced today that new data, including a late-breaking presentation on Tasigna® 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's h...
PR Newswire via Yahoo! Finance,
Tue Dec 01 22:25:00 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News